Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ.
Marshall JL, et al. Among authors: ratain mj.
Invest New Drugs. 2005 Jan;23(1):31-7. doi: 10.1023/B:DRUG.0000047103.64335.b0.
Invest New Drugs. 2005.
PMID: 15528978
Clinical Trial.